Introduction
============

Viral latency is a reversible state whereby a pathogenic virus becomes dormant (latent) during the viral life cycle in individual cells. HIV-1 may either actively replicate to rapidly produce progeny virions or can enter a long-lived quiescent state (viral latency), from which it may later be subsequently reactivated. The mechanisms for establishment and maintenance of HIV-1 latency mainly operate at the transcriptional level by both viral ([@B85]; [@B25]; [@B26]; [@B65]) and host ([@B16], [@B17]; [@B26]) machineries and occur at the levels of transcription, chromatin modification, and epigenetic regulations ([@B16]; [@B26]; [@B5]; [@B11]).

HIV-1 latency is primarily found within resting memory CD4^+^ T cells ([@B15], [@B14]; [@B18]), microglia cells ([@B12]; [@B21]), monocytes/macrophages ([@B6]; [@B40]; [@B1]), and others ([@B8]; [@B50]; [@B78]) which intrinsically have a long half-life *in vivo*. Because the expression level of the viral proteins is absent or poorly expressed and also the existence of immune escape mutations ([@B22]), the latently infected cells are much less susceptible to be recognized and cleared by the host immune system, viral cytopathic effects or currently available antiretroviral drugs. Thus to date, latently infected viral reservoir is one of the fundamental limitations toward HIV cure ([@B51]).

Among the viral proteins, HIV-1 Tat has attracted more attention in viral latency because it potently plays a role in viral transcription regulation. Structurally, Tat is a small nuclear protein with amino acid length ranging from 86 to 101 and the molecular weight ranging from 14 to 16 kDa ([@B71]). Functionally, Tat is divided by six domains and plays a role in nuclear translocation ([@B27]; [@B64]), binding for viral RNA ([@B70]), several host factors and co-factors ([@B36]; [@B30]; [@B52]), and the transactivation of 5′ long terminal repeat (LTR) ([@B71]; [@B70]; [@B36]; [@B76]; [@B57]). Despite such fundamental functions in the virus life cycle, Tat is a highly polymorphic protein comparable to other HIV-1 polymorphic proteins such as Env, Vpu, and Nef ([@B86]; [@B67]). Recent studies indicate that a substantial part of viral polymorphisms including in Tat is caused by viral mutational escape from cellular immune responses ([@B4]; [@B53]; [@B37]; [@B10]). It is conceivable that naturally occurring mutations in Tat may modulate transactivation or other Tat functions, and that consequently affect the establishment and reversal of HIV-1 latency *in vivo*. In this mini review, we will describe the role of HIV-1 Tat toward HIV-1 latency establishment and reactivation, and discuss the possibility that naturally occurring Tat mutations may influence viral latency. The details of host machinery in relation to HIV-1 latency have been well described in recent reviews ([@B72]; [@B18]; [@B11]) and are not discussed here.

The Role of HIV-1 Tat in Establishment of Viral Latency
-------------------------------------------------------

Tat ensures high levels of viral transcription during the virus life cycle ([@B20]). The protein stimulates transcription from the viral 5′ LTR promoter and controls RNA polymerase II (RNAP II) elongation. This is achieved by Tat binding to the TAR hairpin in the nascent RNA transcript and the complex of positive transcription elongation factor b (P-TEFb) composed of Cyclin T1 (CycT1) and cyclin-dependent kinase 9 (CDK9) which phosphorylates the C-terminal domain of the RNAP II that consequently promote transcriptional elongation from the viral promoter (**Figure [1](#F1){ref-type="fig"}**) ([@B19]; [@B59]; [@B20]; [@B62]). Importantly, the absence or inactivation of Tat in HIV-1 infection has been observed to predominantly generate short non-polyadenylated transcripts of less than 100 nucleotides in length that forms the TAR stem-loop structure, and resulted in reduction of viral transcription and replication ([@B29]; [@B70]; [@B84]; [@B58]; [@B20]) (**Figure [1](#F1){ref-type="fig"}**).

![**Tat role in establishment and reversion of viral latency.** The schematic figures illustrate how HIV-1 Tat may contribute to establishment of viral latency and latency reversal in resting memory CD4^+^ T cells in HIV-1 infection.](fmicb-08-00080-g001){#F1}

It could be therapeutically beneficial if we could prevent or at least reduce to a large extent the size of the established latent reservoir. Evidence indicates that Tat, when present in sufficient quantities, may counteract the establishment of HIV-1 latency by promoting transcriptional initiation or elongation ([@B60]; [@B25]). One study demonstrated that fewer latently infected cells were established in Jurkat cells that stably express Tat compared to cells that did not express Tat ([@B25]). These findings highlight the contribution of Tat and its abundance on prevention of establishment of viral latency. In contrast, a complete block of Tat activity may induce permanent latency as observed with use the of Tat dependent transcription inhibitors such as didehydro-cortistatin A (dCA). The agent has been shown to induce permanently the inactivation of the viral transcription in primary latently infected CD4^+^ T cells isolated from aviremic ART-treated subjects; and also when tested in several cell line models of latency (HeLa-CD4, promyelocytic OM-10.1 and J-Lat T-lymphocytic cell lines) ([@B55]). In addition, in the same study both in primary cells and latently infected cell line models, the dCA established a state of latency with an extremely impaired ability to reactivate even in the presence of conventional latency-reversing agents (such as TNF-α and prostratin). Therefore, the concomitant treatment of dCA and antiretroviral drugs may reduce the size of reactivation of latently infected cells *in vivo* and eventually attain a functional HIV cure. However, to date, most experiments done for dCA are limited to *in vitro* models of latently infected cell lines and primary CD4^+^ T cells. Therefore, further studies are needed to test the efficacy and safety of dCA as a viral transcription inhibitor agent in advanced experimental systems such as using humanized mice and non-human primates.

Role of Tat Protein on Reversion of Viral Latency
-------------------------------------------------

Tat can also contribute to reactivation of latently infected cells. For example, previous studies demonstrated that Tat is responsible for directly activating viral transcription in the patient-derived latently infected resting memory CD4^+^ T cells without requiring cellular activation ([@B46]; [@B42]). This is also supported by the Jurkat model of latency showing that the introduction of exogenous Tat was sufficient to reactivate most of the latently infected population ([@B25]). Similarly, HIV-1 latently infected cells, at least in Jurkat cells, can be reactivated by cellular superinfection in a Tat-dependent manner ([@B24]). Moreover, both experimental and computational methods have revealed that Tat is more effective than cellular activation approaches in reactivation of full-length transcription of latent HIV. In a recent study, [@B66] showed that removal of cell activation stimuli in HIV-infected primary CD4^+^ T cells resulted in a drastic decline in cellular activation, but viral transcription activity as measured by GFP expression of productively infected cells remained relatively unchanged. Furthermore, the same study revealed by a computational method of HIV transcriptional modulation that Tat in abundance alone is sufficient for reactivation of the latently infected cells ([@B66]). In addition, the depletion of some host factors or molecules that inhibit Tat transactivation activities, such as the long non-coding RNAs (NRON) that degrades Tat protein, in combination with a histone deacetylase (HDAC) inhibitor, has also been shown to significantly reactivate HIV-1 latency in CD4^+^ T lymphocytes ([@B44]). Furthermore, in a recent mutational study, a Tat mutant, Tat-R5M4 that comprises of V36A, Q66A, V67A, S66A, and S77A mutations, exhibited a potent ability to reactivate latently infected CD4^+^ T lymphocytes ([@B31]). Taken together, these findings provide a potential alternative approach toward reactivation of the latently infected cells with Tat protein.

Effects of Tat Variability on Latency
-------------------------------------

Sequence analysis of plasma viral RNA isolated from cross-sectional and longitudinal collection of HIV-infected individuals exhibited that HIV-1 Tat is a highly variable protein even among the rapidly mutating HIV-1 proteins such as Env, Vpu, and Nef ([@B86]; [@B43]). The high genetic variability of HIV-1 Tat is observed across the subtypes, such as subtypes B and C, in the major HIV-1 group M, and also across HIV-1 groups O and N as well as HIV-2 ([@B86]; [@B67]; [@B43]; [@B69]). Interestingly, Bayesian evolutionary analysis model demonstrated that subtype B Tat has evolved relatively faster than other subtypes ([@B68]). The extent of amino acid variability in Tat as estimated by the Shannon entropy score in subtype B sequences published in Los Alamos sequence database is illustrated in **Figure [2](#F2){ref-type="fig"}**.

![**Amino acid variability, immunogenic sites for CTL, and functionally important sites for transactivation activity of HIV-1 Tat.** The figure depicts the amino acid variability of Tat as measured by the Shannon entropy score for subtype B Tat sequences (*n* = 378) obtained from a public database (Los Alamos Sequence Database). The immune reactive sites are shown with location of CTL epitopes and the amino acid residues that are associated with CTL escape as determined by statistical association with host HLA class I allele (red). Tat~HXB2~ is used as reference. The domains associated with the transactivation activity are also indicated.](fmicb-08-00080-g002){#F2}

Mutational studies of HIV-1 Tat revealed that Tat is divided into six functional domains ([@B41]) (**Figure [2](#F2){ref-type="fig"}**). The first three domains are responsible for Tat transactivation activity and binding with the transcription cofactors ([@B29]; [@B28]; [@B30]; [@B82]; [@B73]); while the fourth domain is a TAR binding domain ([@B23]; [@B70]; [@B81]). The fourth and fifth domains are important for Tat nuclear localization ([@B71]), the sixth domain binds to DNA PK and also contribute to viral infectivity ([@B75]). Importantly in regard to viral latency the functional domains II and III, spanning amino acid positions 22 to 48, are shown to be responsible for transactivation activity (**Figure [2](#F2){ref-type="fig"}**). The several mutations at positions 22 to 40 amino acid residues (including highly conserved cysteine residues) have been shown to be deleterious with respect to Tat transactivation activity; whereas those at positions 1 to 21 amino acid residues are relatively functionally tolerated ([@B41]; [@B71]). Tat plays active role in productive viral replication mainly through enhancement of transcription at viral LTR promoter. Mutational studies have shown there is a strong correlation between Tat transactivation activity and viral replication capacity, whereby the functionally defective Tat has ability to severely inhibit viral replication *in vitro* ([@B79]; [@B20]). This suggests that provirus with functionally defective Tat influences the viral replication and size of the latent reservoir *in vivo*. In respect to the naturally occurring mutations from HIV-1-infected individuals, the Cys-22 to Ser mutation (C22S) in HIV-1 Oyi strain resulted in loss of transactivation activity and was enriched in long-term non-progressive patients ([@B35]; [@B61]; [@B80]). Moreover, several naturally occurring polymorphisms, including P10S, W11R, K19R, A42V, and Y47H, that were observed in 5 HIV-infected subjects at acute or early infection stage, demonstrated impaired transactivation activity and were statistically significantly enriched in the latently infected CD4^+^ T cells ([@B85]). These findings suggest that certain naturally occurring mutations can influence Tat transactivation activity and the establishment of viral latency or reactivation of latent reservoirs during the course of HIV-1 infection *in vivo*. Therefore, this issue warrants for more comprehensive study using a large number of HIV-infected subjects.

Genetic Variability of Tat Driven by Immune-Mediated Selection Forces
---------------------------------------------------------------------

It is becoming evident that mutational escape from CD8^+^ cytotoxic T lymphocyte (CTL) responses represents a potent ongoing driver of global HIV-1 diversification ([@B63]; [@B33]; [@B7]; [@B10]). Tat has also been shown to be frequently targeted by the host HLA-restricted CTL responses ([@B2], [@B3]; [@B83]). A number of CTL epitopes have been identified, including PW9 (^3^PVDPRLEPW^11^) and EW10 (^2^EPVDPNLEPW^11^) restricted by the protective HLA-I alleles, HLA-B^∗^57 and HLA-B^∗^5801, respectively ([@B74]; [@B87]; [@B13]). Additional epitopes are well summarized at the web site, <http://www.hiv.lanl.gov/content/immunology/maps/ctl/Tat.html>. CTL epitopes are distributed in both highly conserved and polymorphic regions in Tat; however, more number of CTL epitopes are reported at the relatively conserved regions to date (**Figure [2](#F2){ref-type="fig"}**). A number of Tat mutations in both conserved and variable regions have been reported to be associated with host cellular immune responses in various viral subtypes and host populations (**Figure [2](#F2){ref-type="fig"}**) ([@B4]; [@B34]; [@B53]; [@B37]; [@B10]). Importantly, some of the CTL escape mutations in Tat such as F32L and V36S observed in a frequently recognized (or immunodominant) Tat epitope, CC8 (^30^CCFHCQVC^37^) restricted by HLA-C^∗^12:03 ([@B9]; [@B48], [@B49]), are located at sites that are important for transactivation and co-factor binding (**Figure [2](#F2){ref-type="fig"}**). Some other CTL escape mutations are located at functionally important regions; N24K, N24T, K29R, and K29S in NF9 (^24^NCYCKRCCF^32^) epitope restricted by HLA-A^∗^29:02 ([@B38]), K40T in FY10 (^38^FQKKGLGISY^47^) restricted by HLA-B^∗^15:03 ([@B47]), and R7S, R7K, and E9D in PW9 (^3^PVDPRLEPW^11^) restricted by HLA-A^∗^25:01 ([@B48]). These data suggest that CTL escape mutations in Tat, especially those located at functionally important conserved regions, have a potential to differentially influence Tat activity. However, it remains elusive as to what extent CTL responses to Tat or CTL escape mutations in Tat may influence viral latency kinetics both at establishment and reversal stages. Also, it is intriguing to ask whether Tat mutations may influence immune recognition of latently infected cells after reactivation. It is also worth to mention that despite the predominant effect of CTL selection pressure on Tat sequence polymorphism, other host immune responses such as those mediated by CD4^+^ T cells ([@B45]; [@B65]) and B cells ([@B32]; [@B54]) also target Tat; and may therefore potentially impose selection pressure leading to escape mutations which may differentially affect Tat activity.

Conclusion and Future Perspectives
==================================

To date, the highly genetic viral variability and the existence of latently infected resting CD4^+^ T lymphocytes and other cells *in vivo* are among the setbacks toward achievement of complete HIV control and eradication. It is generally thought that virus can acquire mutations and evade host immune responses while maintain their fitness effects as minimal as possible. However, similar to the cases in the other HIV-1 proteins such as Gag ([@B33]; [@B77]) and Nef ([@B56]; [@B39]), certain naturally occurring immune-associated mutations in Tat may impose fitness cost to the virus. However, it remains poorly described how immune-mediated Tat polymorphisms affect either establishment of viral latency or reactivation of the latently infected cells and also the consequence of such viral polymorphisms on immune recognition. These points could open a new venue to modulate HIV latency and reversal of latency *in vivo* for future therapeutic application toward cure.
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